Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens

Karin Jordan, Richard Gralla, Giada Rizzi, Kimia Kashef

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy benefit of an NK<sub>1</sub> receptor antagonist (NK<sub>1</sub>RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK<sub>1</sub> RA, netupitant, and palonosetron) and aprepitant regimens'. Together they form a unique fingerprint.

Medicine & Life Sciences